 SAN RAFAEL, Calif., July 21, 2021 PRNewswire -- BioMarin Pharmaceutical Inc. NASDAQ: BMRN announced today new data for valoctocogene roxaparvovec, an investigational gene therapy treatment for adults with severe hemophilia A, from its open-label Phase 12 study during an oral presentation at the International Society on Thrombosis and Haemostasis ISTH 2021 Virtual Congress. 